INTRODUCTION
Immunisation with a live, attenuated bacterial vaccine results in the induction of potent immune responses against the bacterial strain, due to the mimicking of natural infection by the attenuated pathogen. It has been known for some time that attenuated bacterial vaccines also have the potential to deliver heterologous antigens, either expressed from within the bacteria or delivered as a DNA vaccine that is subsequently transferred to host cells for expression (reviewed in [1] ). Several bacterial species have been evaluated for this purpose, and the use of attenuated Salmonella strains as carriers of foreign antigens is a well-studied strategy (reviewed in [2, 3] ). Salmonella enterica serovar Typhimurium (S. typhimurium) is a facultative intracellular pathogen that invades enterocytes and M cells in the intestine. Salmonellosis is an important disease in livestock, causing significant disease in a variety of food animals. It is also an important contributor to gastrointestinal disease in humans, with Salmonella spp. being second only to Campylobacter spp. as the cause of gastroenteritis in people, generally due to the consumption of undercooked food. We have previously reported on the use of an aro A -S. typhimurium vaccine, STM1, for use in poultry [4] . This vaccine can successfully protect chickens from subsequent challenge with virulent Salmonella [5] , and is a registered vaccine that is commercially available to the livestock industry. STM1 has been rigorously evaluated for efficacy and safety in clinical trials and has been shown to be safe in food animals. Consequently it is an excellent candidate for development as a vehicle for the delivery of heterologous sequences for use in the field of veterinary vaccines or for future use for inducing mucosal immunity in humans. In this communication
we describe the evaluation of this potential using a model antigen, ovalbumin. It has been demonstrated by others that Salmonella can deliver antigens to the MHC Class I pathway in vitro [6] .
We have extended the analysis by correlating in vitro antigen presentation by an enriched population of murine dendritic cells with the observed immune responses obtained after vaccination of mice. induces. Given that successful vaccination with encoded heterologous antigen requires the presentation of expressed antigen by antigen-presenting cells (APCs) [15] , the observed utility of S. typhimurium to deliver heterologous antigens to a front-line APC of the host immune system is apparent. 
Transformation of bacteria
Plasmid DNA was maintained in and purified from E. coli DH5a using standard procedures. S.
typhimurium strains were transformed with plasmid DNA according to the following procedure. S.
typhimurium (LT2-9121 or STM1) were cultured in LB broth at 37 o C for 3-4 hours. The culture was then placed on ice for 30 min, the bacteria collected by centrifugation and washed in 20ml of sterile water. The cell pellet was suspended in 2 ml of 10% glycerol/water and again collected by centrifugation. Bacteria were finally resuspended in 500 ml of 10% glycerol/water. One hundred ng of plasmid was transformed into 40 ml of competent cells by electroporation at 25 mF, 2.48 Kv, and 200 ohms, using a Biorad gene pulser. Outgrowth and selection of transformed cells was by standard
Mice
Mice were obtained from the Animal Resource Centre, Perth, Australia and were housed at the animal facility of RMIT University. All mice were female C57BL/6, 6-10 weeks of age.
Cell Culture
Enrichment of dendritic cells (DCs) from bone marrow was as described elsewhere [18] . [19] . These cells were routinely cultured in DMEM.
Antigen Presentation assay
The ability of mammalian cells infected with STM1 carrying ovalbumin-expressing plasmids to stimulate B3Z cells was assessed. Presentation of SIINFEKL via MHC class I to B3Z cells results in the artificial generation of a colorimetric response, allowing a quantitative comparison of antigen presentation to be made [19] . Prior to infection, bacteria were grown to stationary phase, diluted in PBS and opsonized for 30 min in PBS containing 20 % normal mouse serum. In vitro infection was performed as previously described by Cheminay et al [12] , at a multiplicity of infection of 100:1.
Cultured DCs were infected with STM1 carrying plasmid (pKK, pKK-OVA or sOVA-C1) as follows.
Immature DCs were resuspended in complete RPMI (without antibiotics) and seeded at 10 5 cells per well in 24-well plates. 1 x 10 7 STM1 containing the appropriate plasmid were added to each well. The 24 well plates were centrifuged at 270 x g for 5min. Dendritic cells were incubated for 2h at 37 o C.
After infection, cultures were treated with gentamicin (100mg/ml) for one hour and washed twice with PBS. DCs were resuspended in RPMI and cultured overnight. To measure uptake of STM1 by DCs, an aliquot of infected DCs was lysed with Triton X100, and the lysate plated to calculate bacterial counts.
Between 1 and 10% of the original bacterial culture were recovered (10 5 -10 6 cells), demonstrating significant uptake of STM1 by DCs. On the next day 10 5 B3Z cells per well were seeded in 96-well tissue culture plates (Greiner, Germany). Infected DCs were irradiated at 5000 rad for 13 min then distributed at 10 5 cells/well in 100ml. For a positive control, B3Z cells were pulsed with 25 mg/ml SIINFEKL peptide for 2-3 h, followed by washing 3 times. All conditions were analysed in triplicate. Cells were co-cultured overnight at 37 o C, then collected by centrifugation and washed once with PBS. The colourimetric assay was developed as described [20] with some modifications; briefly, the B3Z cells were lysed in 100 ml PBS containing 100 mM 2-mercaptoethanol, 9 mM MgCl 2 , 0.125% NP-40 and 0.15 mM CPRG (chlorophenol red b-galactoside, Calbiochem), and absorbance was measured at 550/650 nm.
Immunization of mice.
Two immunisation experiments were conducted. In the first, groups of 3 mice were vaccinated three times at three weekly intervals with STM1 with and without DNA plasmid (oral vaccination) or naked plasmid DNA (intramuscular vaccination). Vaccination groups are detailed in the results. Oral vaccination was performed by inoculation of 5 x 10 7 CFU and IP vaccination with 1 X 10 5 CFU. For naked DNA vaccination, 50 mg of plasmid DNA in saline was injected into each quadriceps muscle.
Serum samples were taken prior to the third vaccination and three weeks after the third vaccination, at which time mice were killed and splenocytes isolated for ELISPOT. In the second experiment groups of 5 mice were vaccinated either once, or twice at a threeweek interval. Blood was sampled three weeks after the first and (where appropriate) three weeks after the second vaccination. Mice were killed and splenocytes isolated at each of these time points, hence duplicate groups of mice received one or two vaccinations.
Antibody assay
Humoral responses to ovalbumin were analysed by ELISA, using microtitre plates coated with 10 mg/ml grade V chicken ovalbumin (Sigma, USA). Briefly, diluted sera were incubated for 4 hours at room temperature. For the detection of IgG, peroxidase-conjugated goat anti-mouse IgG (Biorad) was added at 1:1000 dilution and incubated at 37 o C for 1 hour, followed by washing and addition of substrate. For isotype detection, rabbit anti mouse IgG1 was diluted to 1:2000, anti mouse IgG2a was diluted to 1:3000 and anti mouse IgA was diluted to 1:1000. Assays were developed by addition of substrate 3,3', 5,5'-tetramethylbenzidin (Sigma, USA).
Cytokine assay
Cytokine secretion by stimulated lymphocytes was detected by using the ELISPOT assay as Figure 1 shows the results from one typical experiment (a second experiment gave similar qualitative, statistically significant results). This shows that the positive control, the peptide SIINFEKL, was able to trigger T cells, and also shows that dendritic cells infected by STM1 carrying ovalbumin-expressing plasmids were also able to do so. These results indicate that dendritic cells can process ovalbumin 
T cell responses are evident after a single vaccination
In the above experiment mice were vaccinated three times prior to evaluation of responses. We also investigated the ability of spleen cells to secrete cytokines after re-stimulation following fewer doses of vaccine. In a second experiment, groups of mice were vaccinated once or twice and T cell responses measured three weeks later. Figure 2B shows that at each time point the responses to STM1 delivering ovalbumin sequences were significantly higher (P < 0.05) than STM1 delivering the empty vector.
Delivery of ovalbumin by STM1 induces humoral responses
It was established in the above experiments that the delivery of ovalbumin sequences by STM1 could induce T cell responses, and in particular, CD8 + responses. We next tested sera from vaccinated mice to evaluate humoral responses to ovalbumin. Figure 3 shows the results from both vaccination experiments. In the first trial, humoral responses were generated in mice vaccinated with either sOVA-C1 naked DNA, pKK-OVA in STM1 or sOVA-C1 in STM1 ( Figure 3A) . These results therefore correlate with the ability of the various vaccines to elicit T cell responses, as detected by ELISPOT.
Only those vaccines that induced a T cell response were able to induce a humoral response. Both IgG1 and IgG2a responses were detected, with IgG2a titres consistently higher than IgG1 titres ( Figure 3B ).
Both conjugates were used well in excess of their titres (1:15,800 and 1:10,200 for IgG1 and IgG2a respectively, used at 1:3000 or less). It was therefore assumed the assays were effectively saturated and the titres can be compared between the two conjugates. This analysis shows that there was IgG2a dominance in the response to ovalbumin, indicating a Th1-type response. We also measured responses to STM1 lysate, and again found higher titres of IgG2a compared to IgG1 (data not shown). Finally, IgA levels were measured. As shown in Figure 3B , all ova-expressing constructs induced the IgA isotype. As expected, the ratio of IgA:IgG1 was higher when the DNA vaccine was delivered orally in STM1 (9:1), rather than as a naked DNA vaccine (1.2:1). sOVA-C1/STM1
